

Date: 8<sup>th</sup> November, 2024

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
1<sup>st</sup> Floor, Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001  
**Scrip Code: 506235**

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Limited  
"Exchange Plaza"  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**NSE Symbol: ALEMBICLTD**

Dear Sir,

**Sub: Outcome of Board Meeting**

With reference to the captioned subject, the exchange is hereby informed that the Board of Directors of Alembic Limited at its meeting held today has *inter alia* approved the Unaudited Financial Results of the Company for the quarter and half year ended 30<sup>th</sup> September, 2024:

We enclose herewith the following:

- a) Consolidated Unaudited Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2024.
- b) Standalone Unaudited Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2024.
- c) Limited Review Report by Statutory Auditors on the Consolidated and Standalone Unaudited Financial Results.

The time of commencement of the Board Meeting was 4:00 p.m. and the time of conclusion was 4:45 p.m.


We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

**For Alembic Limited**

  
**Keval Thakkar**  
**Company Secretary**



Encl.: A/a

**ALEMBIC LIMITED**



**ALEMBIC LIMITED**  
 CIN:L26100GJ1907PLC000033  
 Regd.Office: Alembic Road, Vadodara 390 003  
 Ph:0265 6637000  
 www.alembiclimited.com Email:alembic.investors@alembic.co.in

**Statement of Consolidated Unaudited Financial Results for the Quarter and Half year ended 30th September, 2024**

Rs. in Lakhs

Sr. No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
1	Revenue from Operations	5,291	5,078	3,228	10,370	6,912	15,749
2	Other Income	6,560	196	4,787	6,756	5,051	5,477
3	<b>Total Income</b>	<b>11,852</b>	<b>5,274</b>	<b>8,015</b>	<b>17,126</b>	<b>11,963</b>	<b>21,226</b>
4	<b>Expenses</b>						
	Cost of Materials Consumed	141	286	246	427	380	862
	Cost of Construction	1,659	1,191	796	2,849	1,718	3,981
	Changes in Inventories of Finished Goods and WIP	71	131	(58)	202	189	53
	Employee Benefit Expenses	652	773	563	1,425	1,190	2,303
	Finance Costs	67	49	13	116	27	111
	Depreciation and amortisation expense	268	250	186	518	370	784
	Other Expenses	810	657	665	1,466	1,331	2,864
	<b>Total Expenses</b>	<b>3,669</b>	<b>3,337</b>	<b>2,412</b>	<b>7,006</b>	<b>5,205</b>	<b>10,957</b>
5	<b>Profit Before Tax (3-4)</b>	<b>8,183</b>	<b>1,937</b>	<b>5,603</b>	<b>10,120</b>	<b>6,758</b>	<b>10,269</b>
6	<b>Tax Expenses</b>						
	Current Tax	916	234	534	1,150	647	1,002
	Deferred Tax	(465)	(38)	196	(503)	242	482
	Short / (Excess) Provision of earlier years	(0)	-	(297)	(0)	(297)	(502)
7	<b>Net Profit after tax for the Period</b>	<b>7,731</b>	<b>1,742</b>	<b>5,171</b>	<b>9,474</b>	<b>6,166</b>	<b>9,287</b>
8	<b>Share of Associate's Profit/(Loss)</b>	<b>4,371</b>	<b>3,840</b>	<b>3,897</b>	<b>8,210</b>	<b>7,339</b>	<b>17,575</b>
9	<b>Net Profit/(Loss) after tax and Share of Associate's Profit/(Loss)</b>	<b>12,102</b>	<b>5,582</b>	<b>9,068</b>	<b>17,684</b>	<b>13,506</b>	<b>26,862</b>
10	<b>Other Comprehensive Income</b>						
	A (i) Items that will not be reclassified to Profit or (Loss)	(2,794)	4,348	(3,174)	1,554	830	(6,855)
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	(355)	(490)	367	(845)	(86)	775
	B (i) Items that will be reclassified to Profit or (Loss)	31	(3)	74	28	49	108
11	<b>Total Comprehensive Income/(Loss) for the Period</b>	<b>8,984</b>	<b>9,436</b>	<b>6,334</b>	<b>18,420</b>	<b>14,299</b>	<b>20,890</b>
12	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64
13	Other Equity (excluding Revaluation Reserve)						1,85,911
14	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	4.71	2.17	3.53	6.89	5.26	10.46



Alembic Limited  
Segment wise Consolidated Revenue and Results

Rs. in Lakhs

Sr. No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
1	<b>Segment Revenue</b>						
	Revenue from Operations						
	a. Active Pharmaceutical Ingredients Business	746	1,072	785	1,818	1,729	3,174
	b. Real Estate Business	4,546	4,006	2,442	8,552	5,183	12,574
	<b>Total Income from Operations (Net)</b>	<b>5,291</b>	<b>5,078</b>	<b>3,228</b>	<b>10,370</b>	<b>6,912</b>	<b>15,749</b>
2	<b>Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)</b>						
	a. Active Pharmaceutical Ingredients Business	36	50	92	86	137	336
	b. Real Estate Business	1,786	1,924	849	3,710	1,825	5,126
	<b>Total</b>	<b>1,822</b>	<b>1,974</b>	<b>940</b>	<b>3,796</b>	<b>1,962</b>	<b>5,462</b>
	Unallocable Income and Expenditure						
	(i) Interest Expense	(67)	(49)	(13)	(116)	(27)	(111)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	6,398	31	4,651	6,430	4,775	4,869
	(iii) Other Income / (Expense)	30	(20)	25	11	47	49
	<b>Total Profit Before Tax</b>	<b>8,183</b>	<b>1,937</b>	<b>5,603</b>	<b>10,120</b>	<b>6,758</b>	<b>10,269</b>
3	<b>Segment Assets</b>						
	a. Active Pharmaceutical Ingredients Business	18,215	18,752	18,414	18,215	18,414	18,380
	b. Real Estate Business	41,848	39,663	33,628	41,848	33,628	36,700
	c. Unallocated	1,84,033	1,86,495	1,74,931	1,84,033	1,74,931	1,77,798
	<b>Total</b>	<b>2,44,096</b>	<b>2,44,910</b>	<b>2,26,972</b>	<b>2,44,096</b>	<b>2,26,972</b>	<b>2,32,877</b>
4	<b>Segment Liabilities</b>						
	a. Active Pharmaceutical Ingredients Business	3,291	3,582	2,943	3,291	2,943	2,941
	b. Real Estate Business	12,116	8,987	8,252	12,116	8,252	7,682
	c. Unallocated	4,046	4,349	3,811	4,046	3,811	3,698
	<b>Total</b>	<b>19,453</b>	<b>16,918</b>	<b>15,006</b>	<b>19,453</b>	<b>15,006</b>	<b>14,321</b>

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara  
Date : 8th November, 2024



*[Signature]*  
For Alembic Limited

Chirayu Amin  
Chairman

## Alembic Limited

## Statement of Consolidated Assets and Liabilities

Rs. in Lakhs

Particulars	As at 30th September, 2024 (Unaudited)	As at 31st March, 2024 (Audited)
<b>ASSETS</b>		
<b>Non-Current Assets</b>		
(a) Property, Plant and Equipments	13,115	13,054
(b) Capital Work-in-Progress	22	110
(c) Investment Property	25,388	23,818
(d) Goodwill	5	5
(e) Financial Assets		
(i) Investments	32,890	31,303
(ii) Investments accounted using Equity Method	1,48,143	1,46,162
(iii) Others	1,060	1,186
(f) Other Non-Current Assets	3,500	3,500
	<b>2,24,124</b>	<b>2,19,138</b>
<b>Current Assets</b>		
(a) Inventories	9,705	9,260
(b) Financial Assets		
(i) Investments	3,943	1,134
(ii) Trade Receivables	4,346	1,976
(iii) Cash and Cash Equivalents	175	126
(iv) Bank Balances other than Cash and Cash Equivalents	159	120
(v) Others	299	267
(c) Other Current Assets	1,345	856
	<b>19,972</b>	<b>13,739</b>
<b>TOTAL - ASSETS</b>	<b>2,44,096</b>	<b>2,32,877</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share Capital	5,136	5,136
(b) Other Equity	2,19,507	2,13,421
	<b>2,24,643</b>	<b>2,18,556</b>
<b>Liabilities</b>		
<b>Non-Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	1,263	739
(ii) Other Financial Liabilities	1,247	1,140
(b) Provisions	252	191
(c) Deferred Tax Liability (Net)	3,579	3,219
	<b>6,340</b>	<b>5,289</b>
<b>Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	358	176
(ii) Trade Payables		
a) total outstanding dues of Micro and Small Enterprises	498	656
b) total outstanding dues of Others	2,694	2,447
(iii) Other Financial Liabilities	806	640
(b) Other Current Liabilities	6,121	2,494
(c) Provisions	2,169	2,141
(d) Current Tax Liabilities (Net)	467	479
	<b>13,112</b>	<b>9,032</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>2,44,096</b>	<b>2,32,877</b>

For Alembic Limited

Place : Vadodara  
Date : 8th November, 2024



Chirayu Amin  
Chairman

Alembic Limited

Consolidated Statement of Cash Flow for Half Year ended 30th September, 2024

Rs. In Lakhs

Particulars	For the Half Year Ended on 30th September, 2024 (Unaudited)	For the Half Year Ended on 30th September, 2023 (Unaudited)
<b>A CASH FLOW FROM OPERATING ACTIVITIES:</b>		
Net Profit before tax	10,120	6,758
Add:		
Depreciation	518	370
Interest charged	116	27
(Gain) / Loss on sale of Property, Plant and Equipments	(0)	(16)
Other Non cash items	(157)	(187)
Less:		
Interest Income	(100)	(39)
Dividend Income	(6,295)	(4,591)
<b>Operating Profit before change in working capital</b>	<b>4,204</b>	<b>2,321</b>
<b>Working capital changes:</b>		
Add / (Less) :		
(Increase) / Decrease in Inventories	(445)	208
(Increase) / Decrease in Trade Receivables	(2,370)	193
(Increase) / Decrease in Other Assets	(489)	(4,524)
(Increase) / Decrease in Financial Assets	94	(292)
Increase / (Decrease) in Trade Payables	89	1,247
Increase / (Decrease) in Financial Liabilities	235	66
Increase / (Decrease) in Other Liabilities	3,626	109
Increase / (Decrease) in Provisions	76	52
<b>Cash generated from operations</b>	<b>5,020</b>	<b>(621)</b>
Add / (Less) :		
Direct taxes paid (Net of refunds)	(1,162)	(452)
<b>Net cash inflow from operating activities (A)</b>	<b>3,857</b>	<b>(1,073)</b>
<b>B CASH FLOW FROM INVESTING ACTIVITIES:</b>		
Add:		
Proceeds from sale of Property, Plant and Equipments	0	18
Proceeds from sale / redemption of Investments	8,354	11,363
Interest received	100	39
Dividend received	6,295	4,591
	<b>14,749</b>	<b>16,010</b>
Less:		
Purchase of PPE and Investment Property/increase in CWIP and Capital Advances	2,063	2,701
Purchase of Investments	10,921	6,966
Increase in Restricted Bank Balances other than Cash & Cash Equivalents	38	32
	<b>13,022</b>	<b>9,699</b>
<b>Net cash inflow from Investing activities (B)</b>	<b>1,727</b>	<b>6,312</b>
<b>C CASH FLOW FROM FINANCING ACTIVITIES:</b>		
Add:		
Proceeds from long term borrowings	706	500
Less:		
Dividends paid	6,124	5,617
Interest and other finance costs	116	27
	<b>6,241</b>	<b>5,644</b>
<b>Net cash inflow from Financing activities (C)</b>	<b>(5,535)</b>	<b>(5,144)</b>
<b>I. Net (Decrease) / Increase in cash and cash equivalents (A+B+C)</b>	<b>49</b>	<b>95</b>
<b>II. Cash and cash equivalents at the beginning of the period</b>	<b>126</b>	<b>93</b>
<b>III. Cash and cash equivalents at the end of the period (I+II)</b>	<b>175</b>	<b>188</b>
<b>IV. Cash and cash equivalents at the end of the period</b>		
Balances with Bank	174	187
Cash on Hand	1	1
<b>Cash and cash equivalents</b>	<b>175</b>	<b>188</b>

For Alembic Limited

Place : Vadodara  
Date : 8th November, 2024



*Chirayu Amin*

Chirayu Amin  
Chairman

**Statement of Standalone Unaudited Financial Results for the Quarter and Half year ended 30th September, 2024**

**Rs. in Lakhs**

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
1	Revenue from Operations	5,110	4,908	3,115	10,018	6,680	15,225
2	Other Income	6,559	189	4,786	6,748	5,045	5,462
3	<b>Total Income</b>	<b>11,669</b>	<b>5,097</b>	<b>7,901</b>	<b>16,766</b>	<b>11,725</b>	<b>20,687</b>
4	<b>Expenses</b>						
	Cost of Materials Consumed	141	286	246	427	380	862
	Cost of Construction	1,659	1,191	796	2,849	1,718	3,981
	Changes in Inventories of Finished Goods and WIP	71	131	(58)	202	189	53
	Employee Benefit Expenses	652	773	563	1,425	1,190	2,303
	Finance Costs	51	34	5	85	10	69
	Depreciation and amortisation expense	259	241	177	499	351	746
	Other Expenses	749	582	606	1,331	1,229	2,402
	<b>Total Expenses</b>	<b>3,582</b>	<b>3,238</b>	<b>2,334</b>	<b>6,820</b>	<b>5,067</b>	<b>10,415</b>
5	<b>Profit Before Tax (3-4)</b>	<b>8,087</b>	<b>1,859</b>	<b>5,566</b>	<b>9,946</b>	<b>6,658</b>	<b>10,272</b>
6	<b>Tax Expenses</b>						
	Current Tax	892	213	525	1,105	620	1,000
	Deferred Tax	(465)	(37)	196	(502)	243	484
	Short / (Excess) Provision of earlier years	(0)	-	(297)	(0)	(297)	(501)
7	<b>Net Profit after tax for the Period</b>	<b>7,660</b>	<b>1,684</b>	<b>5,143</b>	<b>9,343</b>	<b>6,092</b>	<b>9,289</b>
8	<b>Other Comprehensive Income</b>						
	(i) Items that will not be reclassified to Profit or (Loss)	(2,801)	4,459	(3,117)	1,658	890	(6,409)
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	(354)	(510)	367	(863)	(86)	747
9	<b>Total Comprehensive Income/(Loss) for the Period</b>	<b>4,505</b>	<b>5,633</b>	<b>2,394</b>	<b>10,137</b>	<b>6,896</b>	<b>3,627</b>
10	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64
11	Other Equity (excluding Revaluation Reserve)						48,231
12	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	2.98	0.66	2.00	3.64	2.37	3.62



Alembic Limited  
Segment wise Standalone Revenue and Results

Rs. in Lakhs


Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
1	<b>Segment Revenue</b>						
	Revenue from Operations						
	a. Active Pharmaceutical Ingredients Business	746	1,072	785	1,818	1,729	3,174
	b. Real Estate Business	4,364	3,835	2,330	8,200	4,951	12,051
	<b>Total Income from Operations (Net)</b>	<b>5,110</b>	<b>4,908</b>	<b>3,115</b>	<b>10,018</b>	<b>6,680</b>	<b>15,225</b>
2	<b>Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)</b>						
	a. Active Pharmaceutical Ingredients Business	36	50	92	86	137	336
	b. Real Estate Business	1,674	1,831	804	3,505	1,708	5,087
	<b>Total</b>	<b>1,710</b>	<b>1,881</b>	<b>895</b>	<b>3,591</b>	<b>1,845</b>	<b>5,423</b>
	Unallocable Income and Expenditure						
	(i) Interest Expense	(51)	(34)	(5)	(85)	(10)	(69)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	6,398	31	4,651	6,430	4,775	4,869
	(iii) Other Income / (Expense)	30	(20)	25	11	47	49
	<b>Total Profit Before Tax</b>	<b>8,087</b>	<b>1,859</b>	<b>5,566</b>	<b>9,946</b>	<b>6,658</b>	<b>10,272</b>
3	<b>Segment Assets</b>						
	a. Active Pharmaceutical Ingredients Business	18,215	18,752	18,414	18,215	18,414	18,380
	b. Real Estate Business	40,917	38,784	32,819	40,917	32,819	35,897
	c. Unallocated	44,564	45,057	47,323	44,564	47,323	40,310
	<b>Total</b>	<b>1,03,697</b>	<b>1,02,592</b>	<b>98,556</b>	<b>1,03,697</b>	<b>98,556</b>	<b>94,587</b>
4	<b>Segment Liabilities</b>						
	a. Active Pharmaceutical Ingredients Business	3,291	3,582	2,943	3,291	2,943	2,941
	b. Real Estate Business	11,264	8,154	7,659	11,264	7,659	6,941
	c. Unallocated	4,291	4,347	3,808	4,291	3,808	3,829
	<b>Total</b>	<b>18,846</b>	<b>16,084</b>	<b>14,410</b>	<b>18,846</b>	<b>14,410</b>	<b>13,711</b>


Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited

Place : Vadodara  
Date : 8th November, 2024



  
Chirayu Amin  
Chairman

## Alembic Limited

## Statement of Standalone Assets and Liabilities

Rs. in Lakhs

Particulars	As at 30th September, 2024 (Unaudited)	As at 31st March, 2024 (Audited)
<b>ASSETS</b>		
<b>Non-Current Assets</b>		
(a) Property, Plant and Equipments	13,115	13,054
(b) Capital Work-in-Progress	22	110
(c) Investment Property	25,119	23,529
(d) Financial Assets		
(i) Investments	41,564	39,978
(ii) Others	938	1,064
(e) Other Non-Current Assets	3,500	3,500
	<b>84,259</b>	<b>81,235</b>
<b>Current Assets</b>		
(a) Inventories	9,705	9,260
(b) Financial Assets		
(i) Investments	3,755	1,086
(ii) Trade Receivables	4,110	1,740
(iii) Cash and Cash Equivalents	131	99
(iv) Bank Balances other than Cash and Cash Equivalents	159	120
(v) Others	299	267
(c) Other Current Assets	1,279	780
	<b>19,438</b>	<b>13,352</b>
<b>TOTAL - ASSETS</b>	<b>1,03,697</b>	<b>94,587</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share Capital	5,136	5,136
(b) Other Equity	79,715	75,740
	<b>84,851</b>	<b>80,876</b>
<b>Liabilities</b>		
<b>Non-Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	1,263	739
(ii) Other Financial Liabilities	704	646
(b) Provisions	252	191
(c) Deferred Tax Liability (Net)	3,578	3,217
	<b>5,796</b>	<b>4,793</b>
<b>Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	358	176
(ii) Trade Payables		
a) total outstanding dues of Micro and Small Enterprises	474	652
b) total outstanding dues of Others	2,649	2,389
(iii) Other Financial Liabilities	670	535
(b) Other Current Liabilities	6,016	2,413
(c) Provisions	2,169	2,141
(d) Current Tax Liabilities (Net)	713	612
	<b>13,050</b>	<b>8,918</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>1,03,697</b>	<b>94,587</b>

For Alembic Limited

Place : Vadodara  
Date : 8th November, 2024

*[Signature]*  
Chairman




**Alembic Limited**  
**Standalone Statement of Cash Flow for Half Year ended 30th September, 2024**

Rs. in Lakhs

Particulars	For the Half Year Ended on 30th September, 2024 (Unaudited)	For the Half Year Ended on 30th September, 2023 (Unaudited)
<b>A CASH FLOW FROM OPERATING ACTIVITIES:</b>		
Net Profit before tax	9,946	6,658
Add:		
Depreciation	499	351
Interest charged	85	10
(Gain) / Loss on sale of Property, Plant and Equipments	(0)	(16)
Other Non cash items	(154)	(184)
Less:		
Interest Income	(100)	(38)
Dividend Income	(6,295)	(4,591)
<b>Operating Profit before change in working capital</b>	<b>3,982</b>	<b>2,189</b>
<b>Working capital changes:</b>		
Add / (Less) :		
(Increase) / Decrease in Inventories	(445)	208
(Increase) / Decrease in Trade Receivables	(2,370)	260
(Increase) / Decrease in Other Assets	(499)	(4,497)
(Increase) / Decrease in Financial Assets	94	(292)
Increase / (Decrease) in Trade Payables	82	1,203
Increase / (Decrease) in Financial Liabilities	154	269
Increase / (Decrease) in Other Liabilities	3,603	92
Increase / (Decrease) in Provisions	76	52
<b>Cash generated from operations</b>	<b>4,676</b>	<b>(517)</b>
Add / (Less) :		
Direct taxes paid (Net of refunds)	(1,004)	(395)
<b>Net cash inflow from operating activities (A)</b>	<b>3,672</b>	<b>(912)</b>
<b>B CASH FLOW FROM INVESTING ACTIVITIES:</b>		
Add:		
Proceeds from sale of Property, Plant and Equipments	0	18
Proceeds from sale / redemption of Investments	8,351	11,046
Interest received	100	38
Dividend received	6,295	4,591
Less:		
Purchase of PPE and Investment Property/increase in CWIP and Capital Advances	2,063	2,684
Purchase of Investments	10,781	6,886
Increase in Restricted Bank Balances other than Cash & Cash Equivalents	38	32
	12,882	9,602
<b>Net cash inflow from Investing activities (B)</b>	<b>1,864</b>	<b>6,090</b>
<b>C CASH FLOW FROM FINANCING ACTIVITIES:</b>		
Add:		
Proceeds from long term borrowings	706	500
Less:		
Dividends paid	6,124	5,617
Interest and other finance costs	85	10
	6,210	5,627
<b>Net cash inflow from Financing activities (C)</b>	<b>(5,504)</b>	<b>(5,127)</b>
<b>I. Net (Decrease) / Increase in cash and cash equivalents (A+B+C)</b>	<b>32</b>	<b>52</b>
<b>II. Cash and cash equivalents at the beginning of the period</b>	<b>99</b>	<b>83</b>
<b>III. Cash and cash equivalents at the end of the period (I+II)</b>	<b>131</b>	<b>135</b>
<b>IV. Cash and cash equivalents at the end of the period</b>		
Balances with Bank	130	134
Cash on Hand	1	1
<b>Cash and cash equivalents</b>	<b>131</b>	<b>135</b>

For Alembic Limited

Place : Vadodara  
Date : 8th November, 2024



  
Chirayu Amin  
Chairman

Independent Auditor's Review Report on Unaudited Consolidated Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of **Alembic Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30<sup>th</sup> September, 2024 and year to date from 1<sup>st</sup> April, 2024 to 30<sup>th</sup> September, 2024 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.


**4. Emphasis of Matter**

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous periods, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability in the Consolidated Financial Statements for the year ended 31<sup>st</sup> March, 2024. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26<sup>th</sup> May, 2023 and the appeal filed by the Company has been admitted.

Our opinion is not modified in respect of above matter.


The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: [www.cnkindia.com](http://www.cnkindia.com)



5. The statement includes results of the following entities:
- Alembic City Limited (Subsidiary)
  - Alembic Pharmaceuticals Limited (Associate)
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose unaudited financial results reflect (before consolidated adjustments) total assets of Rs. 14,582.02 lakhs as at 30<sup>th</sup> September, 2024, total revenue of Rs. 928.40 lakhs and Rs. 1,817.02 lakhs, total net loss after tax of Rs. 41.54 lakhs and Rs. 93.84 lakhs and total comprehensive loss of Rs. 41.32 lakhs and Rs. 93.64 lakhs for the quarter ended 30<sup>th</sup> September, 2024 and the period ended on that day respectively and net cash inflow of Rs. 16.85 lakhs for the period from 1<sup>st</sup> April, 2024 to 30<sup>th</sup> September, 2024. The unaudited consolidated financial results also include the Group's share of net profit after tax of Rs. 4,370.78 lakhs and Rs. 8,210.47 lakhs and total comprehensive income of Rs. 4,407.88 lakhs and Rs. 8,152.25 lakhs for the quarter ended 30<sup>th</sup> September, 2024 and the period ended on that day respectively, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For C N K & Associates LLP  
Chartered Accountants  
Firm Registration No. 101961W/W-100036



Rachit Sheth

Partner

Membership No.158289

Place: Vadodara

Date: 8<sup>th</sup> November, 2024

UDIN: 24158289BKAQRC7611



Independent Auditor's Review Report on Unaudited Standalone Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of Alembic Limited ("the Company") for the quarter ended 30<sup>th</sup> September, 2024 and year to date from 01<sup>st</sup> April, 2024 to 30<sup>th</sup> September, 2024 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

#### 4. Emphasis of Matter

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous periods, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability in the Standalone Financial Statements for the year ended 31<sup>st</sup> March, 2024. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26<sup>th</sup> May, 2023 and the appeal filed by the Company has been admitted.

Our opinion is not modified in respect of above matter.

The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: [www.cnkindia.com](http://www.cnkindia.com)



5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For C N K & Associates LLP  
Chartered Accountants  
Firm Registration No. 101961W/W-100036

*Rachit*

Rachit Sheth

Partner

Membership No.158289

Place: Vadodara

Date: 8<sup>th</sup> November, 2024

UDIN: 24158289BKAQRB8660

